Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance of [14C]CCX168 in Healthy Volunteers
NCT06004960Phase 1Completed
- Sponsor
- Amgen
- Start
- Oct 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of avacopan in Antineutrophil cytoplasmic antibody-associated vasculitis (AAV), sponsored by Amgen. Primary endpoints: Cumulative Percentage of the Administered Dose of [14C]CCX168 Recovered in Urine at Day 15 and Cumulative Percentage of the Administered Dose of [14C]CCX168 Recovered in Feces at Day 15. Started Oct 2014; status: completed.
02
Drugs
avacopan
03
Conditions
Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT06004960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06004960.